Zarko Manojlovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zarko Manojlovic has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- David Wesley Craig
Beckman Research Institute, City of Hope
21 shared publications - Arlene Naranjo
Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL
19 shared publications - Emily Hibbitts
Department of Biostatistics, University of Florida, Children's Oncology Group, Gainesville, FL
19 shared publications - Fan F. Zhang
Children's Oncology Group Statistics and Data Center, Monrovia, CA
19 shared publications - Julie R. Park
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
19 shared publications - Meredith S. Irwin
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
19 shared publications
Latest Publications
- Open Access
Analysis of Naturally Arising Simple Deletions in Single Human Colon Crypts with Age
Changes of DNA sequence in the human genome may contribute to human aging, but it has been difficult for the field to define the details of the contribution. Cancer cells have altered ratios of DNA damage and repair pathways, and thus it is inappropriate to utilize them as models for normal cells. Also, somatic mutations from each lineage cannot be clearly identified in cell populations with multiple lineages. Normal human colon crypts are one of the few mini-organ systems where monoclonal cell populations can be found for somatic mutation analysis. In a parallel study, we described complex insertion/deletion (indel) events in normal human colon. Here we focus on simple deletions that lack any nucleotide addition or adjacent base substitutions. We find that ∼58% of the simple deletions are consistent with a strand slippage event, and the remainder provide insights into other important repair processes. Among the 4,264 ≥2-nucleotide simple deletions, ∼71% are most consistent with nonhomologous DNA end joining (NHEJ), with <1.5% of the events being more consistent with alternative end joining (aEJ). The incidence of NHEJ-type simple deletions is ∼8-fold more frequent than the complex indels that also show NHEJ features. Similar to the complex indels, the simple deletions show a linear trend of event accumulation (positive slope) with an overall ∼10-fold increase in absolute number across the human lifespan, 0.8 months to 90 years old, for individuals with no radiation or chemotherapy treatment. Interestingly, radiation treatment increases non-slippage deletions with little effect on slip deletions.
Open AccessAnalysis of Naturally Arising Simple Deletions in Single Human Colon Crypts with Age
Changes of DNA sequence in the human genome may contribute to human aging, but it has been difficult for the field to define the details of the contribution. Cancer cells have altered ratios of DNA damage and repair pathways, and thus it is inappropriate to utilize them as models for normal cells. Also, somatic mutations from each lineage cannot be clearly identified in cell populations with multiple lineages. Normal human colon crypts are one of the few mini-organ systems where monoclonal cell populations can be found for somatic mutation analysis. In a parallel study, we described complex insertion/deletion (indel) events in normal human colon. Here we focus on simple deletions that lack any nucleotide addition or adjacent base substitutions. We find that ∼58% of the simple deletions are consistent with a strand slippage event, and the remainder provide insights into other important repair processes. Among the 4,264 ≥2-nucleotide simple deletions, ∼71% are most consistent with nonhomologous DNA end joining (NHEJ), with <1.5% of the events being more consistent with alternative end joining (aEJ). The incidence of NHEJ-type simple deletions is ∼8-fold more frequent than the complex indels that also show NHEJ features. Similar to the complex indels, the simple deletions show a linear trend of event accumulation (positive slope) with an overall ∼10-fold increase in absolute number across the human lifespan, 0.8 months to 90 years old, for individuals with no radiation or chemotherapy treatment. Interestingly, radiation treatment increases non-slippage deletions with little effect on slip deletions.
- Open Access
SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma
Purpose: SWI/SNF (BAF) chromatin remodeling complex alterations are common in urothelial carcinoma, yet no biomarker-directed therapeutic strategies have been established for this population. We investigated whether BAF alterations delineate a biologically distinct, therapeutically actionable urothelial carcinoma subtype. Experimental Design: We performed integrative genomic and transcriptomic analyses of 792 urothelial carcinoma tumors from the Oncology Research Information Exchange Network (ORIEN) and validated findings in the TCGA-BLCA cohort. Mechanistic studies incorporated RNA sequencing and ATAC-seq following histone deacetylase (HDAC) inhibition. Functional dependencies were assessed using patient-derived xenograft organoids and cell line models. Clinical relevance was explored in a biomarker-enriched investigator-initiated trial. Results: Approximately half of urothelial carcinoma tumors exhibited BAF alterations, defining a previously unrecognized chromatin-altered molecular subtype characterized by activation of proliferative programs, loss of lineage identity, and altered metabolic signaling. This subtype was enriched for transcriptomic programs associated with HDAC inhibitor sensitivity and depleted of HDAC inhibitor resistance signatures. Mechanistically, HDAC inhibition induced widespread chromatin remodeling with reduced accessibility at AP-1 and TEAD-associated regions, and downregulation of E2F- and MYC-driven transcriptional networks. Functional studies confirmed enhanced HDAC inhibition sensitivity in ARID1A -mutated cell lines and a patient-derived organoid model. Early clinical observations demonstrated a durable responder treated with HDAC inhibitors and immunotherapy. Conclusions: BAF alterations define a chromatin-dependent tumor state in urothelial carcinoma that is selectively vulnerable to HDAC inhibition. Integrating genomic, epigenomic, functional, and early clinical evidence, these findings provide a rationale for biomarker-enriched clinical trials and HDAC inhibitor-based combination strategies in urothelial carcinoma.
Open AccessSWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial Carcinoma
Purpose: SWI/SNF (BAF) chromatin remodeling complex alterations are common in urothelial carcinoma, yet no biomarker-directed therapeutic strategies have been established for this population. We investigated whether BAF alterations delineate a biologically distinct, therapeutically actionable urothelial carcinoma subtype. Experimental Design: We performed integrative genomic and transcriptomic analyses of 792 urothelial carcinoma tumors from the Oncology Research Information Exchange Network (ORIEN) and validated findings in the TCGA-BLCA cohort. Mechanistic studies incorporated RNA sequencing and ATAC-seq following histone deacetylase (HDAC) inhibition. Functional dependencies were assessed using patient-derived xenograft organoids and cell line models. Clinical relevance was explored in a biomarker-enriched investigator-initiated trial. Results: Approximately half of urothelial carcinoma tumors exhibited BAF alterations, defining a previously unrecognized chromatin-altered molecular subtype characterized by activation of proliferative programs, loss of lineage identity, and altered metabolic signaling. This subtype was enriched for transcriptomic programs associated with HDAC inhibitor sensitivity and depleted of HDAC inhibitor resistance signatures. Mechanistically, HDAC inhibition induced widespread chromatin remodeling with reduced accessibility at AP-1 and TEAD-associated regions, and downregulation of E2F- and MYC-driven transcriptional networks. Functional studies confirmed enhanced HDAC inhibition sensitivity in ARID1A -mutated cell lines and a patient-derived organoid model. Early clinical observations demonstrated a durable responder treated with HDAC inhibitors and immunotherapy. Conclusions: BAF alterations define a chromatin-dependent tumor state in urothelial carcinoma that is selectively vulnerable to HDAC inhibition. Integrating genomic, epigenomic, functional, and early clinical evidence, these findings provide a rationale for biomarker-enriched clinical trials and HDAC inhibitor-based combination strategies in urothelial carcinoma.
- Open Access
Mutation count and mutation profile analyses of single-nucleotide variants in single human colon crypts
Genetic heterogeneity due to the accumulation of mutations in normal tissues can increase cancer risk and be an important factor in many age-related degenerative and chronic diseases. Somatic mutations can arise from DNA damage or replication errors and accumulate in normal tissues with age. We obtained high depth whole genome sequencing data to comprehensively profile somatic mutations in 106 single human colon crypts with matched bulk controls from 21 individuals age 10 months to 90 years old. Our analysis reveals that about half of the human crypts are polyclonal (multi-lineage) instead of entirely monoclonal as conventionally construed. Consequently, the DNA mutation count would be inflated, while the variant allele frequency for each variant would be reduced in the cell population of a multi-lineage colon crypt. Therefore, our mutation count analysis includes using single stem cell lineage colon crypts exclusively to establish the somatic mutation rate for each of the 96 trinucleotide mutation categories. In addition, the mutation profile, representing the relative presence of the 96 trinucleotide mutation categories, in each colon crypt is analyzed. Unlike mutation count, the mutation profile is not affected by crypt clonality and is very similar across all ages in individuals with no chemotherapy or radiation treatment. Importantly, combined results from mutation count and mutation profile analyses of individuals with chemotherapy or radiation suggest an intriguing impact of these treatments on cell survival. The baseline mutation rate and the normal mutation profile established in our study provide a framework for a genomic standard to assess biological age and deviations associated with factors such as lifestyle, age-related degenerative and chronic diseases, and potentially cancer treatment outcome. Future studies similar to this current study on other tissues can provide further insight into how and why different tissues age differently in humans.
Open AccessMutation count and mutation profile analyses of single-nucleotide variants in single human colon crypts
Genetic heterogeneity due to the accumulation of mutations in normal tissues can increase cancer risk and be an important factor in many age-related degenerative and chronic diseases. Somatic mutations can arise from DNA damage or replication errors and accumulate in normal tissues with age. We obtained high depth whole genome sequencing data to comprehensively profile somatic mutations in 106 single human colon crypts with matched bulk controls from 21 individuals age 10 months to 90 years old. Our analysis reveals that about half of the human crypts are polyclonal (multi-lineage) instead of entirely monoclonal as conventionally construed. Consequently, the DNA mutation count would be inflated, while the variant allele frequency for each variant would be reduced in the cell population of a multi-lineage colon crypt. Therefore, our mutation count analysis includes using single stem cell lineage colon crypts exclusively to establish the somatic mutation rate for each of the 96 trinucleotide mutation categories. In addition, the mutation profile, representing the relative presence of the 96 trinucleotide mutation categories, in each colon crypt is analyzed. Unlike mutation count, the mutation profile is not affected by crypt clonality and is very similar across all ages in individuals with no chemotherapy or radiation treatment. Importantly, combined results from mutation count and mutation profile analyses of individuals with chemotherapy or radiation suggest an intriguing impact of these treatments on cell survival. The baseline mutation rate and the normal mutation profile established in our study provide a framework for a genomic standard to assess biological age and deviations associated with factors such as lifestyle, age-related degenerative and chronic diseases, and potentially cancer treatment outcome. Future studies similar to this current study on other tissues can provide further insight into how and why different tissues age differently in humans.
- Open Access
Complex Indel Detection: A Simulation-Based Framework and Parsing with FreeBayes
In contrast to simple deletions and simple insertions, most complex indels involve both deletions and insertions, often with base changes within a few nucleotides of the indel’s left and right boundaries. These complex indels often arise from double-strand breaks (DSB), which in normal somatic cells are predominantly repaired by nonhomologous DNA end joining (NHEJ). Such complex indels pose a difficult analytical problem for existing indel callers because the observed VCF representation may be locally shifted, extended with matching flanking bases, or fragmented into several closely spaced calls. To evaluate complex indel representation, we tested six variant calling approaches: FreeBayes, HaplotypeCaller, Mutect2, Strelka2, DRAGEN Germline, and DRAGEN Somatic pipelines. Among the approaches evaluated, FreeBayes most consistently represented simulated complex indels as single nearby variant records. We then developed a parsing workflow that derives effective deleted and inserted sequences from FreeBayes VCF output and enriches for candidate complex indels. This approach supports analysis of naturally occurring DSB repair events in single human colon crypts.
Open AccessComplex Indel Detection: A Simulation-Based Framework and Parsing with FreeBayes
In contrast to simple deletions and simple insertions, most complex indels involve both deletions and insertions, often with base changes within a few nucleotides of the indel’s left and right boundaries. These complex indels often arise from double-strand breaks (DSB), which in normal somatic cells are predominantly repaired by nonhomologous DNA end joining (NHEJ). Such complex indels pose a difficult analytical problem for existing indel callers because the observed VCF representation may be locally shifted, extended with matching flanking bases, or fragmented into several closely spaced calls. To evaluate complex indel representation, we tested six variant calling approaches: FreeBayes, HaplotypeCaller, Mutect2, Strelka2, DRAGEN Germline, and DRAGEN Somatic pipelines. Among the approaches evaluated, FreeBayes most consistently represented simulated complex indels as single nearby variant records. We then developed a parsing workflow that derives effective deleted and inserted sequences from FreeBayes VCF output and enriches for candidate complex indels. This approach supports analysis of naturally occurring DSB repair events in single human colon crypts.
- Open Access
Germline VCF Annotator: a lightweight pipeline for processing germline VCFs with robust variant extraction and read evidence quality control
Raw variant calls are typically distributed as VCF files and are not well-suited for direct human review. They are intended for programmatic parsing, and spreadsheet import can distort data through automatic type conversion. Furthermore, variants in VCF are commonly annotated to add gene context and predicted functional consequences. Ensembl VEP, a widely used standard for transcript-aware variant annotation, was adapted in this study to generate standardized consequence fields across genomic features. Using a colon crypt whole-genome sequencing cohort as the motivating dataset, this study examined whether variation at DNA damage response and repair (DDR) loci could contribute to mutation-burden patterns in normal colon crypts, including patterns associated with age and potential treatment-related exposure. To make this question testable in a reproducible table-based format, the Germline VCF Annotator was developed as a two-step workflow that normalizes germline VCFs, generates VEP tabular annotations with explicit allele fields, and then extracts variants of interest and appends read-evidence metrics to assign a rules-based QC class. Within-patient concordance across technical repeats at predefined DDR loci was near-perfect after filtering for nonsilent SNVs with read depth ≥15, with discordance concentrated among Low-QC loci. Bulk and crypt-derived samples showed no age-related trend in DDR burden. Although the demonstration centers on DDR and aging, the Germline VCF Annotator is applicable to other gene sets that require human-readable locus-level summaries with retained allele provenance and read evidence.
Open AccessGermline VCF Annotator: a lightweight pipeline for processing germline VCFs with robust variant extraction and read evidence quality control
Raw variant calls are typically distributed as VCF files and are not well-suited for direct human review. They are intended for programmatic parsing, and spreadsheet import can distort data through automatic type conversion. Furthermore, variants in VCF are commonly annotated to add gene context and predicted functional consequences. Ensembl VEP, a widely used standard for transcript-aware variant annotation, was adapted in this study to generate standardized consequence fields across genomic features. Using a colon crypt whole-genome sequencing cohort as the motivating dataset, this study examined whether variation at DNA damage response and repair (DDR) loci could contribute to mutation-burden patterns in normal colon crypts, including patterns associated with age and potential treatment-related exposure. To make this question testable in a reproducible table-based format, the Germline VCF Annotator was developed as a two-step workflow that normalizes germline VCFs, generates VEP tabular annotations with explicit allele fields, and then extracts variants of interest and appends read-evidence metrics to assign a rules-based QC class. Within-patient concordance across technical repeats at predefined DDR loci was near-perfect after filtering for nonsilent SNVs with read depth ≥15, with discordance concentrated among Low-QC loci. Bulk and crypt-derived samples showed no age-related trend in DDR burden. Although the demonstration centers on DDR and aging, the Germline VCF Annotator is applicable to other gene sets that require human-readable locus-level summaries with retained allele provenance and read evidence.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES), and Schwann cell profile (SCP) gene signatures.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES), and Schwann cell profile (SCP) gene signatures.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Purpose:Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations. The impact of select clinical and biological factors on overall survival (OS) and event-free survival (EFS) were evaluated.Experimental Design:Patients enrolled on Children's Oncology Group (COG) A3973 (n = 34), ANBL0532 (n = 27), and/or biology protocol ANBL00B1 (n = 72) were analyzed. Tumors with available DNA (n = 65) and RNA (n = 42) were subjected to whole-exome sequencing (WES) and RNA sequencing. WES analyses and gene expression profiling were evaluated for their impact on survival. Multivariate analyses of EFS/OS using significant factors from univariate analyses were performed.Results:5-year EFS/OS for patients treated with high-risk therapy on A3973 and ANBL0532 were 73.0% ± 8.1%/87.9% ± 5.9% and 61.4% ± 10.2%/73.0% ± 9.2%, respectively (P = 0.1286 and P = 0.2180). In the A3973/ANBL0532 cohort, patients with less than partial response (PR; n = 5) at end-induction had poor outcomes (5-year EFS/OS: 0%/20.0% ± 17.9%. Univariate analyses of WES data revealed that subjects whose tumors had chromosome 1p or 11q loss/LOH and chromosome 5 or 9 segmental chromosomal aberrations had inferior EFS compared with those with tumors without these aberrations. Multivariate analysis revealed that 11q loss/LOH was an independent predictor of inferior OS [HR, 3.116 (95% confidence interval, 1.034–9.389), P = 0.0435].Conclusions:Patients ≥18 months of age at diagnosis who had tumors with UH and MYCN-NA INSS stage 3 neuroblastoma assigned to high-risk therapy had an 81.6% ± 5.3% 5-year OS. Less than PR to induction therapy and chromosome 11q loss/LOH are independent predictors of inferior outcome and identify patients who should be eligible for future high-risk clinical trials.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Purpose:Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations. The impact of select clinical and biological factors on overall survival (OS) and event-free survival (EFS) were evaluated.Experimental Design:Patients enrolled on Children's Oncology Group (COG) A3973 (n = 34), ANBL0532 (n = 27), and/or biology protocol ANBL00B1 (n = 72) were analyzed. Tumors with available DNA (n = 65) and RNA (n = 42) were subjected to whole-exome sequencing (WES) and RNA sequencing. WES analyses and gene expression profiling were evaluated for their impact on survival. Multivariate analyses of EFS/OS using significant factors from univariate analyses were performed.Results:5-year EFS/OS for patients treated with high-risk therapy on A3973 and ANBL0532 were 73.0% ± 8.1%/87.9% ± 5.9% and 61.4% ± 10.2%/73.0% ± 9.2%, respectively (P = 0.1286 and P = 0.2180). In the A3973/ANBL0532 cohort, patients with less than partial response (PR; n = 5) at end-induction had poor outcomes (5-year EFS/OS: 0%/20.0% ± 17.9%. Univariate analyses of WES data revealed that subjects whose tumors had chromosome 1p or 11q loss/LOH and chromosome 5 or 9 segmental chromosomal aberrations had inferior EFS compared with those with tumors without these aberrations. Multivariate analysis revealed that 11q loss/LOH was an independent predictor of inferior OS [HR, 3.116 (95% confidence interval, 1.034–9.389), P = 0.0435].Conclusions:Patients ≥18 months of age at diagnosis who had tumors with UH and MYCN-NA INSS stage 3 neuroblastoma assigned to high-risk therapy had an 81.6% ± 5.3% 5-year OS. Less than PR to induction therapy and chromosome 11q loss/LOH are independent predictors of inferior outcome and identify patients who should be eligible for future high-risk clinical trials.
- Open Access
- 26 August 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (9) , 2166-2176
Mutational landscape of triple-negative breast cancer in African American women
African American (AA) women have the highest incidence of triple-negative breast cancer (TNBC) among all ancestral groups, but are underrepresented in cancer genomic studies. In 462 AA women with TNBC, we characterized the tumor mutational landscape by whole-exome sequencing and RNA sequencing. We unveiled a high-resolution mutational portrait of TNBC in AA women reminiscent of that in Chinese and non-Hispanic white women, with no evidence of associations of mutational features with African ancestry. We also made some distinctive discoveries, including an almost complete dominance of TP53 mutations, low frequency of PIK3CA mutations and mutational signature-based subtypes with etiologic and prognostic significance. These findings do not support major ancestral differences in TNBC biology at the level of somatic mutations. Our study contributes considerably to diversifying the knowledge base of breast cancer genomics and provides insights into the disease etiology, disparities and therapeutic vulnerability of TNBC in AA women.
- 26 August 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (9) , 2166-2176
Open AccessMutational landscape of triple-negative breast cancer in African American women
African American (AA) women have the highest incidence of triple-negative breast cancer (TNBC) among all ancestral groups, but are underrepresented in cancer genomic studies. In 462 AA women with TNBC, we characterized the tumor mutational landscape by whole-exome sequencing and RNA sequencing. We unveiled a high-resolution mutational portrait of TNBC in AA women reminiscent of that in Chinese and non-Hispanic white women, with no evidence of associations of mutational features with African ancestry. We also made some distinctive discoveries, including an almost complete dominance of TP53 mutations, low frequency of PIK3CA mutations and mutational signature-based subtypes with etiologic and prognostic significance. These findings do not support major ancestral differences in TNBC biology at the level of somatic mutations. Our study contributes considerably to diversifying the knowledge base of breast cancer genomics and provides insights into the disease etiology, disparities and therapeutic vulnerability of TNBC in AA women.